Psoriasis - a review of recent progress, characteristics, diagnostic management
DOI:
https://doi.org/10.12775/JEHS.2023.13.02.021Keywords
psoriasis, therapy, pathogenesisAbstract
Introduction: Psoriasis is a common, chronic, systemic inflammatory disease with an immunological basis. It occurs in about 2% of people in Europe and North America. It is associated with an increased probability of obesity, diabetes, dyslipidemia, cardiovascular disease and inflammatory bowel disease.
Objective: The purpose of this review is to analyze the latest information on the characteristics, diagnosis and treatment of patients with psoriasis.
Materials and methods: The present study was based on available data collected in the PubMed database and published between 2001 and 2022. The study was conducted by reviewing keywords such as: "psoriasis," "diagnosis," "treatment," "genetics," "immunology," "angiogenesis," "keratinocytes," and "incidence."
State of the knowledge: In the last decade, biologic drugs targeting tumor necrosis factor alpha, interleukin 23, interleukin 17 and interleukin 12 have been developed and approved for the treatment of psoriasis. These drugs have revolutionized the treatment and management of psoriasis.
Summary: Over the past decade, there have been tremendous advances in knowledge about the pathogenesis of psoriasis. Discoveries on this background, have given rise to new biological therapies. Currently in clinical trials are substances such as, Janus kinase inhibitors and tyrosine kinase 2 inhibitors, which represent hope for the most affected patients. Unfortunately, our knowledge of the causes of psoriasis is still incomplete. This poses a challenge for further research and thus the creation of more therapeutic substances.
References
J. E. Guðjónsson i in., „HLA-Cw6-Positive and HLA-Cw6-Negative Patients with Psoriasis Vulgaris have Distinct Clinical Features”, Journal of Investigative Dermatology, t. 118, nr 2, s. 362–365, luty 2002, doi: 10.1046/j.0022-202x.2001.01656.x.
W. Łuszczek i in., „Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris”, Human Immunology, t. 65, nr 7, s. 758–766, 2004, doi: 10.1016/j.humimm.2004.05.008.
E. M. Farber i L. Nall, „The Natural History of Psoriasis in 5,600 Patients”, Dermatology, t. 148, nr 1, s. 1–18, 1974, doi: 10.1159/000251595.
R. P. Nair i in., „Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis Susceptibility 1 Gene”, The American Journal of Human Genetics, t. 78, nr 5, s. 827–851, maj 2006, doi: 10.1086/503821.
J. T. Elder i in., „Molecular dissection of psoriasis: Integrating genetics and biology”, Journal of Investigative Dermatology, t. 130, nr 5, s. 1213–1226, 2010, doi: 10.1038/jid.2009.319.
F. Capon i in., „Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis”, Human Genetics, t. 122, nr 2, s. 201–206, 2007, doi: 10.1007/s00439-007-0397-0.
N. Wolf i in., „Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease”, Journal of Medical Genetics, t. 45, nr 2, s. 114–116, 2008, doi: 10.1136/jmg.2007.053595.
A. Di Cesare, P. Di Meglio, i F. O. Nestle, „The IL-23Th17 axis in the immunopathogenesis of psoriasis”, Journal of Investigative Dermatology, t. 129, nr 6, s. 1339–1350, 2009, doi: 10.1038/jid.2009.59.
E. Bettelli, M. Oukka, i V. K. Kuchroo, „TH-17 cells in the circle of immunity and autoimmunity”, Nat Immunol, t. 8, nr 4, s. 345–350, kwi. 2007, doi: 10.1038/ni0407-345.
R. R. M. C. Keijsers i in., „In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17”, Journal of Investigative Dermatology, t. 134, nr 5, s. 1276–1284, 2014, doi: 10.1038/jid.2013.526.
C. Costa, J. Incio, i R. Soares, „Angiogenesis and chronic inflammation: Cause or consequence?”, Angiogenesis, t. 10, nr 3, s. 149–166, 2007, doi: 10.1007/s10456-007-9074-0.
P. M. Elias i in., „Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: Implications for the pathogenesis of psoriasis”, American Journal of Pathology, t. 173, nr 3, s. 689–699, 2008, doi: 10.2353/ajpath.2008.080088.
M. Detmar i in., „Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.”, Journal of Experimental Medicine, t. 180, nr 3, s. 1141–1146, wrz. 1994, doi: 10.1084/jem.180.3.1141.
K. Kuroda, A. Sapadin, T. Shoji, R. Fleischmajer, i M. Lebwohl, „Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis”, Journal of Investigative Dermatology, t. 116, nr 5, s. 713–720, 2001, doi: 10.1046/j.1523-1747.2001.01316.x.
T. Markham i in., „Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy”, Journal of the American Academy of Dermatology, t. 54, nr 6, s. 1003–1012, 2006, doi: 10.1016/j.jaad.2006.01.038.
K. Reich, „The concept of psoriasis as a systemic inflammation: Implications for disease management”, Journal of the European Academy of Dermatology and Venereology, t. 26, nr SUPPL. 2, s. 3–11, 2012, doi: 10.1111/j.1468-3083.2011.04410.x.
C. E. Griffiths i J. N. Barker, „Pathogenesis and clinical features of psoriasis”, The Lancet, t. 370, nr 9583, s. 263–271, lip. 2007, doi: 10.1016/S0140-6736(07)61128-3.
M. Łuczkowska i R. Żaba, „Łuszczyca”, Przewodnik Lekarza/Guide for GPs, t. 8, nr 7, s. 38–49, 2005.
S. H. Omland i R. Gniadecki, „Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?”, Clinics in Dermatology, t. 33, nr 4, s. 456–461, lip. 2015, doi: 10.1016/j.clindermatol.2015.04.007.
U. Mrowietz i in., „Definition of treatment goals for moderate to severe psoriasis: A European consensus”, Archives of Dermatological Research, t. 303, nr 1, s. 1–10, 2011, doi: 10.1007/s00403-010-1080-1.
J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, i W. Kirch, „Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials”, British Journal of Dermatology, t. 159, nr 3, s. 513–526, 2008, doi: 10.1111/j.1365-2133.2008.08732.x.
Z. Z. N. Yiu i in., „Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)”, British Journal of Dermatology, t. 180, nr 2, s. 329–337, 2019, doi: 10.1111/bjd.17036.
A. Reich i in., „Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2”, pd, t. 107, nr 2, s. 110–137, 2020, doi: 10.5114/dr.2020.95259.
J. E. Hawkes, T. C. Chan, i J. G. Krueger, „Psoriasis pathogenesis and the development of novel targeted immune therapies”, Journal of Allergy and Clinical Immunology, t. 140, nr 3, s. 645–653, 2017, doi: 10.1016/j.jaci.2017.07.004.
A. Reich i in., „Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2”, pd, t. 107, nr 2, s. 110–137, 2020, doi: 10.5114/dr.2020.95259.
K. Reich i in., „Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial”, The Lancet, t. 394, nr 10201, s. 831–839, 2019, doi: 10.1016/S0140-6736(19)31773-8.
J. J. Crowley, R. B. Warren, i J. C. Cather, „Safety of selective IL-23p19 inhibitors for the treatment of psoriasis”, Journal of the European Academy of Dermatology and Venereology, t. 33, nr 9, s. 1676–1684, 2019, doi: 10.1111/jdv.15653.
A. Chiricozzi, D. Caposiena, V. Garofalo, M. V. Cannizzaro, S. Chimenti, i R. Saraceno, „A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast”, Expert Review of Clinical Immunology, t. 12, nr 3, s. 237–249, 2016, doi: 10.1586/1744666X.2016.1134319.
W. Damsky i B. A. King, „JAK inhibitors in dermatology: The promise of a new drug class”, Journal of the American Academy of Dermatology, t. 76, nr 4, s. 736–744, 2017, doi: 10.1016/j.jaad.2016.12.005.
K. Papp i in., „Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis”, New England Journal of Medicine, t. 379, nr 14, s. 1313–1321, 2018, doi: 10.1056/nejmoa1806382.
J. A. Singh i in., „Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis”, Arthritis Care and Research, t. 71, nr 1, s. 2–29, 2019, doi: 10.1002/acr.23789.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Paweł Warzyszak, Róża Małek, Maria Milczek, Wojciech Żołyniak, Mikołaj Tomasik, Izabela Hawranik, Szymon Niski, Ziemowit Żaba, Aleksandra Lisowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 926
Number of citations: 0
